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Tamoxifen has held ‘pole position’ in the adjuvant treat-
ment of receptor-positive early breast cancer for over
15 years, ever since the first world overview in 1985 [1]. It
has also been approved for and widely prescribed in the
chemoprevention of breast cancer in the United States
since the publication of the P-1 trial [2]. Two recent publi-
cations challenge this long-lasting supremacy: namely, the
Anastrozole, Tamoxifen Alone or in Combination (ATAC)
trial for adjuvant therapy [3], and the IBIS (International
Breast Intervention Study) trial for primary prevention [4].
In all modesty, I am in an almost unique position to
comment on this challenge. I was the principle investigator
of the Nolvadex Adjuvant Trial Organisation [5], which was
the first to suggest that tamoxifen had a significant effect
on delaying recurrences in the adjuvant treatment of early
breast cancer. Jack Cuzick and I were also the first to
draw attention to the fact that adjuvant tamoxifen signifi-
cantly reduced the incidence of contralateral breast
cancer [6]. Fifteen to 20 years later, I now find myself as
principal investigator of the ATAC trial and a co-author of
the IBIS trial, whose principal investigator is my colleague
Jack Cuzick.
I therefore believe it is time to reappraise the role of
tamoxifen in  both the adjuvant and preventive settings,
and to seriously consider whether the oral aromatase
inhibitors are contenders for the ‘gold standard’ prize.
The ATAC trial and its implication for adjuvant
and chemopreventive regimens
Although tamoxifen is generally well tolerated and rela-
tively nontoxic, it has become clear during the past
decade that prolonged use of this agent is associated with
significant gynaecological complications, including prolif-
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erative endometrial abnormalities in postmenopausal
women. An increased incidence of endometrial cancer has
been reported in association with tamoxifen treatment [7]
and the level of risk appears to be time and dose depen-
dent. Most studies involving tamoxifen have found the
increased relative risk of developing endometrial cancer
while taking tamoxifen to be two to three times higher than
that of an age-matched population [8]. The incidence and
pattern of this increase in endometrial changes suggest
that the underlying mechanism may be related to the
oestrogenic properties of tamoxifen. Other side effects
related to the oestrogenic properties of tamoxifen include
the increased risk of thromboembolic disorders [9].
Most patients who exhibit an initial response to tamoxifen
will eventually develop resistance to treatment [10]. Many
of these patients, however, respond to both second-line
and third-line endocrine therapies, indicating that resis-
tance is not necessarily due to a complete loss of
hormone responsiveness. In view of this, alternative
agents to tamoxifen are now required to treat breast
cancer patients.
The third generation of oral aromatase inhibitors lend them-
selves ideally as candidates either to enhance the activity
of tamoxifen or to replace it entirely in the adjuvant setting.
The ATAC trial in postmenopausal breast cancer patients
with early breast cancer is the first report of a new-genera-
tion aromatase inhibitor compared with tamoxifen in the
early breast cancer setting [3]. An interesting feature of this
trial was the inclusion of the combination arm, hence allow-
ing the investigation of any possible additive effects through
the use of two drugs with different modes of action. It is
possible that anastrozole, by depleting the oestrogen recep-
tor (ER) of its natural ligand while allowing tamoxifen to exert
its beneficial effect via saturation of the receptor, could act
synergistically in treating early breast cancer.
The ATAC study has been reported in detail [3] but it is
worth reviewing in order to clearly understand the
message that might have an immediate impact on clinical
practice around the world.
Postmenopausal patients with operable invasive breast
cancer, who had completed their primary treatment (which
included chemotherapy in about 20% of cases who were
judged to be at very high risk of relapse) and who were
candidates to receive adjuvant hormonal therapy, were ran-
domized with their informed consent. The patients were
randomized to one of three groups: 1.0 mg anastrozole
daily plus a placebo for tamoxifen; 20 mg tamoxifen daily
plus a placebo for anastrozole; or a combination of the two
active agents. A total of 9366 patients from 380 centres in
21 countries were recruited. Five years of treatment were
selected for both drugs bearing in mind the optimum dura-
tion for tamoxifen and the wish to remain blinded. We of
course have no idea of the optimum duration for anastro-
zole. It also should be noted that the analysis was triggered
by a predetermined number of events when the median
duration on therapy was only about 2.5 years.
To understand some of the important subgroup findings, it
must be emphasized that the chemotherapy involved
those with extensive lymph node involvement but also
implied a delay in the start of the allocated endocrine
therapy by about 6 months. Furthermore, in many parts of
Europe for what was a truly global study, the entry criteria
included ER status unknown. However, most of the blocks
were retrieved and classified by immunohistochemistry to
an ER category. This provided an interesting subgroup.
Disease-free survival was significantly prolonged for
patients receiving anastrozole alone compared with those
who received either tamoxifen alone (hazard ratio
[HR] = 0.83, 0.71–0.96;  P = 0.013) or the combination
(HR = 0.81, 0.70–0.94; P = 0.006). The combination was
not significantly different from tamoxifen alone (HR = 1.02,
0.89–1.18; P = 0.8).
When these patients were censored at the time of death,
the HR for time to recurrence (including new tumours)
was further reduced in the anastrozole arm compared with
that of tamoxifen alone (HR = 0.79, 0.67–0.94;
P = 0.008). In comparison with the combination treatment,
anastrozole alone also showed a greater benefit for this
endpoint (HR = 0.75, 0.63–0.89; P = 0.0007). No differ-
ence was observed, however, between the arm receiving
tamoxifen alone and the combination arm (HR = 1.06,
0.90–1.24; P = 0.5).
As expected, the standard prognostic factors predicted
recurrence. The recurrence rate was more than three
times higher in hormone receptor-negative women than in
those who were hormone receptor-positive.
Two interactions of anastrozole or tamoxifen with potential
predictive factors are worthy of comment. The hormone
receptor status was close to significance, with the com-
parison of effects of treatments in the receptor-positive
subgroup being predefined in the protocol. In other words,
the two drugs were equally ineffective in the ER subgroup.
An interaction, close to significance, within the group
receiving chemotherapy first was unexpected and not fully
understood. Two possible explanations are being consid-
ered: a chance imbalance of key prognostic factors
(unlikely), or some unexplained mechanism linked to the
delay in starting the endocrine therapy. Alternatively,
tamoxifen might be performing better than anticipated
because, by the design of the trial, it was provided at the
end of chemotherapy rather than concurrently (Intergroup215
trial 0100 presented at the American Society of Clinical
Oncology, Orlando, FL, USA, May 2002; principal investi-
gator Kathy Albain). Nevertheless, as we expect tamoxifen
to provide added value to chemotherapy, we can predict
that anastrozole and tamoxifen are close to equivalent in
this setting. This issue requires further events and longer
follow-up before any firm conclusions can be drawn on the
relative efficacy of anastrozole and tamoxifen after primary
chemotherapy treatment.
A striking reduction in contralateral breast primaries as a
first event was found in the anastrozole arm of the trial
when compared with that of tamoxifen; the odds were
reduced by 58%.
Most of the contralateral breast cancers were invasive
(83%). When the analysis was restricted to these invasive
events, the difference was somewhat larger (nine patients
in the anastrozole arm versus 30 in the tamoxifen arm
versus 23 in the combination arm; odds ratio of anastro-
zole versus tamoxifen = 0.30, 0.14–0.63; P = 0.0014).
Tolerability of tamoxifen and anastrozole
There was no distinguishable difference as far as side
effects were concerned between tamoxifen alone and the
combination. In comparison with tamoxifen alone,
however, the profile for anastrozole alone was very differ-
ent, and in most cases was more beneficial. In particular,
there were statistically significant and medically relevant
reductions in hot flushes, vaginal discharge, vaginal bleed-
ing, ischaemic cerebrovascular events, venous thrombo-
embolic events and endometrial cancer when receiving
anastrozole alone. Endometrial cancers were reduced by
77% from 13 cases in the tamoxifen arm to three in the
anastrozole arm (P = 0.02). In contrast, musculoskeletal
disorders (i.e. polyarthralgia) and fractures were signifi-
cantly increased. The greatest increase in fractures on
anastrozole treatment appeared to be in the spine, but no
increase of hip fractures was seen.
What can we conclude from the ATAC trial?
Endocrine therapy for breast cancer has enjoyed a remark-
able renaissance since the introduction of tamoxifen in the
1970s. It has been estimated that about two-thirds of the
observed fall in breast cancer mortality in the UK since the
late 1970s can be attributed to this agent [11].
Of course, tamoxifen is not without its problems. Although
relatively well tolerated compared with cytotoxic
chemotherapy, about 30% of women on treatment com-
plain of hot flushes, vaginal discharge and vaginal bleed-
ing. Less common, although much more serious, is the
long-term risk of endometrial cancer and of thrombo-
embolic disease. It has been estimated that, for every
endometrial cancer death, 80 breast cancer deaths have
been avoided. Nevertheless, fear of this complication
prompts transvaginal ultrasound scans and hysteroscopy
in a large number of those women complaining of gynae-
cological symptoms, placing additional pressure on over-
stretched services.
Anastrozole shows superior efficacy to tamoxifen at this
relatively early stage of follow-up, with a 17% relative risk
reduction in disease-free survival in the intention-to-treat
population and a 19% improvement when compared with
the combination arm. Although statistically significant and
impressive in relative terms, this still only translates into an
absolute improvement in disease-free survival of 2–3%. It
is of course too early to be able to describe outcomes in
terms of all-cause and cause-specific mortality, bearing in
mind that the median duration of therapy was only about
2.5 years out of the intended 5 years of treatment. It also
needs to be noted that a disproportionate number of early
events where among the less informative HR-negative and
HR-unknown groups.
The most surprising result was for the combination group,
which fared no better than tamoxifen alone and fared sig-
nificantly worse than anastrozole alone. One possible
explanation is that in an oestrogen-deprived environment
tamoxifen is ‘seen’ as an agonist, whereas in a normal
oestrogen-rich environment tamoxifen can exert its classi-
cal anti-oestrogen effect. Support for this viewpoint comes
from the nude mouse xenograft experiments [12].
Although a rare event, the fear of endometrial cancer asso-
ciated with exposure to tamoxifen means that most of
those women with gynaecological symptoms might have
been subjected to invasive investigations. This advantage
for anastrozole could, in the long term, save much unnec-
essary anxiety and health service costs.
The disadvantages of anastrozole compared with tamoxifen
are found in the contrast between women with chronic
oestrogen deprivation compared with women on a drug
with a weak agonist effect. This can already be noted in
the modest but significant excess of fractures already
observed in the anastrozole group. Whether this is a result
of the protective effect of tamoxifen on bone compared
with an untreated population, or whether it is due to
oestrogen deprivation because of aromatase inhibition, is
at this stage speculative. In pragmatic terms, of course, it
does not matter what the mechanism is because women
will have to make an informed choice between one drug or
the other; no treatment is not an option except in cases
with an extremely good prognosis.
Nevertheless, excess fractures are a side effect that can
be managed if anticipated. Clinicians opting to start
women on anastrozole should request a baseline bone
density scan, which should be repeated at perhaps 12-
month intervals. Women whose bone density starts to fall
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into the osteopaenic range could be considered for a
variety of options. For example, stopping anastrozole if
they have been on treatment for more than 3 years
(bearing in mind the relatively small difference in absolute
benefit between 2 and 5 years of therapy) or starting on a
bisphosphonate, which as well as protecting the skeleton
might even reduce the risk of skeletal metastases [13].
Perhaps the most impressive result of the ATAC trial at
this stage is the near 60% reduction in the incidence of
contralateral invasive cancers for anastrozole treatment
compared with tamoxifen treatment. Yet tamoxifen has
been known to be associated with a significant reduction
in contralateral disease compared with a control popula-
tion since 1985 [1]. In the latest overview, 5 years of
tamoxifen is associated with a 50% reduction in the con-
tralateral breast cancer [14]. These observations have
been translated into a prevention setting for high-risk
women in the National Surgical Adjuvant Breast and
Bowel Project P-1 study [2].
If these trends in the incidence of contralateral breast
cancers persist, then anastrozole has the potential to
prevent (or delay) up to 80% of all cancers. These obser-
vations have already been acted on in the design of the
second UK/ANZ prevention trial, IBIS II (J Cuzick, personal
communication).
The IBIS trial and the future of tamoxifen as a
chemopreventive agent
Three clinical trials have reported on the use of tamoxifen to
prevent breast cancer, with mixed results [2,15,16]. The
overall evidence supports a reduction in the risk of develop-
ing breast cancer, but it is unclear whether this benefit out-
weighs the risks and side effects associated with tamoxifen.
The IBIS trial, which has just been reported [4], in my mind
clarifies the issue beyond doubt. This was a double-blind
placebo-controlled trial conducted in 7140 women at
increased risk of breast cancer, aged 35–70 years. The
primary outcome measure was breast cancer incidence
(including ductal carcinoma in situ). Other cancers, vascu-
lar disease, side effects and mortality were secondary
endpoints.
A total of 169 breast cancers were observed in both arms
(tamoxifen versus placebo) combined. There was a 33%
(CI 9–51) reduction in breast cancer incidence associ-
ated with tamoxifen compared with placebo (68 versus
101 cases, P = 0.01). Endometrial cancer was increased
about twofold (11 versus five cases) but failed to reach
conventional levels of significance (P = 0.2). Thromboem-
bolic events were substantially increased (odds ratio =
2.6, CI 1.7–4.2, P < 0.0001). Vasomotor and gynaeco-
logic symptoms were increased, but benign breast com-
plaints were decreased. Overall, there was a significant
excess of deaths in the tamoxifen arm compared with
placebo (25 patients versus 10 patients, P = 0.016). This
was primarily due to an excess of cardiac and vascular
deaths.
The increased incidence of gynaecologic problems, partic-
ularly the increased requirement for hysterectomy and
oophorectomy, is of some concern. These may be a result
of an increased incidence of vaginal bleeding, of endome-
trial polyps, of endometrial thickening or of ovarian cysts.
All these gynaecological sequelae of tamoxifen and their
investigation must have a profound negative impact on the
quality of life of otherwise well women.
The relatively low breast cancer death rate highlights the
importance of a full evaluation of side effects. The excess
mortality in the tamoxifen arm seen in the IBIS trial may in
part be due to statistical variability. However, the excess of
thromboembolic events seen in all trials and the smaller
excess of thromboembolic deaths seen in the IBIS trial
and the P-1 study do indicate that this is the most impor-
tant complication of tamoxifen use, and that every effort
should be taken to reduce this risk.
While it is clear that tamoxifen can reduce the incidence of
ER-positive breast cancer, the overall risk/benefit ratio for
tamoxifen in the preventive setting is still unclear at present.
Further long-term follow-up study of breast cancer inci-
dence and mortality, other causes of death and side effects
in the ongoing trials remain essential. For the time being,
tamoxifen for the prevention of breast cancer has to be
considered either experimental or ‘with a great future
behind it’. I am clearly not alone in this belief as the steering
committee designing the IBIS II trial have dropped tamox-
ifen as the control in favour of a placebo to compare with
anastrozole (J Cuzick, personal communication).
Conclusions
Although one of the first to propose it, I no longer believe
that tamoxifen has a role in the chemoprevention of breast
cancer. I think what has happened in America in this
regard is a great mistake. I believe that the P-1 study was
presented too early and its follow-up was aborted too
soon. For this reason, the currently recruiting STAR trial
comparing tamoxifen with raloxifene will be uninter-
pretable, for want of a placebo control group, in spite of its
astronomical investment in dollars and volunteers [17].
I believe it is premature to abandon tamoxifen in the adju-
vant setting but at least there is a real choice for the first
time in nearly 20 years. For example, in my opinion, elderly
women with a relatively short life expectancy because of
comorbidity, with or without an increased risk for thrombo-
embolic disease, would be better off on anastrozole than
tamoxifen. As for the rest, I predict that a further year or
two of follow-up in the ATAC trial should resolve the issue.
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In the meantime the ATAC steering committee has agreed
to close down the combined arm but continue the
monotherapy arms blinded within the study. Tamoxifen
may not have had long enough to express its full potential
and we remain concerned about the long-term effects of
aromatase inhibitors on bone mineral metabolism.
Once we’ve sorted out the ethical issues concerning the
archival material in this study, our pathology sub commit-
tee, chaired by Prof. Mitch Dowsett, will begin work on the
microarrays to allow us to search for predictive factors of
response. In particular we are interested to find out if over-
expression of ErbB-2 results in a preferential benefit from
anastrozole, and we can therefore be selective in our
choice of adjuvant therapy according to the specific
tumour phenotype. What an historical step forward that
would be? However, until that golden day dawns I will
hedge my bets, breast cancer that enigmatic disease, will
never cease to surprise us.
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